Red blood cell minor antigen mismatches during chronic transfusion therapy for sickle cell anemia

Transfusion

Volumn 57, Issue 11, 2017, Pages 2738-2746

  Yee, Marianne E M ^a   Josephson, Cassandra D ^a   Winkler, Anne M ^a   Webb, Jennifer ^b   Luban, Naomi L C ^b   Leong, Traci ^c   Stowell, Sean R ^a   Fasano, Ross M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ERYTHROCYTE ANTIBODY; ERYTHROCYTE ANTIGEN; JS ANTIBODY; JS ANTIGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALLOIMMUNIZATION; ARTICLE; BLOOD GROUP TYPING; CHILD; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; GENETIC VARIATION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PEDIATRICS; PHENOTYPE; PRESCHOOL CHILD; SCHOOL CHILD; SICKLE CELL ANEMIA; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT; BLOOD; BLOOD GROUP INCOMPATIBILITY; COMPLICATION; ERYTHROCYTE; GENOTYPE; IMMUNOLOGY; PROCEDURES; STANDARDS;

ADOLESCENT; ANEMIA, SICKLE CELL; BLOOD GROUP INCOMPATIBILITY; BLOOD GROUPING AND CROSSMATCHING; CHILD; CHILD, PRESCHOOL; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; GENOTYPE; HUMANS; ISOANTIBODIES;

EID: 85032882942     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14282     Document Type: Article

References (34)

1. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 1990;76:1431.
2. Vichinsky EP, Earles A, Johnson RA, et al. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990;322:1617-21.
3. Chou ST, Liem RI, Thompson AA. Challenges of alloimmunization in patients with haemoglobinopathies. Br J Haematol 2012;159:394-404.
4. Chou ST, Jackson T, Vege S, et al. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013;122:1062-71.
5. Castro O, Sandler SG, Houston-Yu P, et al. Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion 2002;42:684-90.
6. Sins JW, Biemond BJ, van den Bersselaar SM, et al. Early occurrence of red blood cell alloimmunization in patients with sickle cell disease. Am J Hematol 2016;91:763-9.
7. Lasalle-Williams M, Nuss R, Le T, et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion 2011;51:1732-9.
8. Ambruso DR, Githens JH, Alcorn R, et al. Experience with donors matched for minor blood group antigens in patients with sickle cell anemia who are receiving chronic transfusion therapy. Transfusion 1987;27:94-8.
9. Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001;41:1086-92.
10. Sakhalkar VS, Roberts K, Hawthorne LM, et al. Allosensitization in patients receiving multiple blood transfusions. Ann N Y Acad Sci 2005;1054:495-9.
11. O'Suoji C, Liem RI, Mack AK, et al. Alloimmunization in sickle cell anemia in the era of extended red cell typing. Pediatr Blood Cancer 2013;60:1487-91.
12. Telen MJ, Afenyi-Annan A, Garrett ME, et al. Alloimmunization in sickle cell disease: changing antibody specificities and association with chronic pain and decreased survival. Transfusion 2015;55:1378-87.
13. Nickel RS, Hendrickson JE, Fasano RM, et al. Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series. Transfusion 2016;56:107-14.
14. Cox JV, Steane E, Cunningham G, et al. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Arch Intern Med 1988;148:2485-9.
15. Petz LD, Calhoun L, Shulman IA, et al. The sickle cell hemolytic transfusion reaction syndrome. Transfusion 1997;37:382-92.
16. Higgins JM, Sloan SR. Stochastic modeling of human RBC alloimmunization: evidence for a distinct population of immunologic responders. Blood 2008;112:2546-53.
17. Casas J, Friedman DF, Jackson T, et al. Changing practice: red blood cell typing by molecular methods for patients with sickle cell disease. Transfusion 2015;55:1388-93.
18. Fasano RM, Chou ST. Red blood cell antigen genotyping for sickle cell disease, thalassemia, and other transfusion complications. Transfus Med Rev 2016;30:197-201.
19. Chou ST, Fasano RM. Management of patients with sickle cell disease using transfusion therapy: guidelines and complications. Hematol Oncol Clin North Am 2016;30:591-608.
20. Evidence-based management of sickle cell disease. Washington (DC): U.S. Department of Health and Human Services; 2014.
21. Hashmi G. Red blood cell antigen phenotype by DNA analysis. Transfusion 2007;47:60S-3S.
22. Hashmi G, Shariff T, Zhang Y, et al. Determination of 24 minor red blood cell antigens for more than 2000 blood donors by high-throughput DNA analysis. Transfusion 2007;47:736-47.
23. Hashmi G, Shariff T, Seul M, et al. A flexible array format for large-scale, rapid blood group DNA typing. Transfusion 2005;45:680-8.
24. Dang JP, Maurice CB, Orengo L, Stack G. Blood group genotype testing on leukoreduced RBC segments: establishing the feasibility of hospital-based donor genotyping. AABB. Anaheim, CA: Transfusion 2015;142A.
25. Tournamille C, Colin Y, Cartron JP, et al. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat Genet 1995;10:224-8.
26. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014;312:1033-48.
27. Hendrickson JE, Tormey CA. Understanding red blood cell alloimmunization triggers. Hematology Am Soc Hematol Educ Program 2016;2016:446-51.
28. Fasano RM, Booth GS, Miles M, et al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol 2015;168:291-300.
29. Stowell SR, Girard-Pierce KR, Smith NH, et al. Transfusion of murine red blood cells expressing the human KEL glycoprotein induces clinically significant alloantibodies. Transfusion 2014;54:179-89.
30. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 2012;120:528-37.
31. Karafin MS, Field JJ, Gottschall JL, et al. Barriers to using molecularly typed minority red blood cell donors in support of chronically transfused adult patients with sickle cell disease. Transfusion 2015;55:1399-406.
32. Gehrie EA, Tormey CA. The influence of clinical and biological factors on transfusion-associated non-ABO antigen alloimmunization: responders, hyper-responders, and non-responders. Transfus Med Hemother 2014;41:420-9.
33. McPherson ME, Anderson AR, Castillejo MI, et al. HLA alloimmunization is associated with RBC antibodies in multiply transfused patients with sickle cell disease. Pediatr Blood Cancer 2010;54:552-8.
34. Nickel RS, Hendrickson JE, Yee MM, et al. Red blood cell transfusions are associated with HLA class I but not H-Y alloantibodies in children with sickle cell disease. Br J Haematol 2015;170:247-56.